Skip to main content



24-06-2022 | Rheumatology | News | Article

Counseling intervention boosts breastfeeding rates among women with RA

Women with active rheumatoid arthritis who receive pregnancy counseling are as likely to breastfeed their children as women in the general population, indicate findings from the Preconceptional Counselling in Active Rheumatoid Arthritis study.

23-06-2022 | Rheumatology | News | Article

TNF inhibitor tapered T2T strategy feasible in PsA and axSpA

A tapering treat-to-target strategy can lead to a large reduction in TNF inhibitor dose without impacting disease control in people with psoriatic arthritis or axial spondyloarthritis, study findings indicate.

21-06-2022 | Rheumatology | News | Article

Low-dose glucocorticoids show no negative impact on BMD

Low glucocorticoid doses are not associated with reduced bone mineral density in people with inflammatory rheumatic and musculoskeletal diseases, observational study findings indicate.

20-06-2022 | Rheumatology | News | Article

Predictors of complete remission in SLE identified

Research has revealed factors associated with complete remission in patients with systemic lupus erythematosus, including lack of renal involvement and antiphospholipid syndrome, White ethnicity, and older age at diagnosis.

17-06-2022 | Rheumatology | News | Article

Walking for exercise ‘should be encouraged’ in people with knee osteoarthritis

Findings from an observational study suggest that walking for exercise is associated with a reduced risk for developing frequent knee pain among people aged 50 years and older with knee osteoarthritis.

16-06-2022 | Rheumatology | News | Article

Targeted therapy not linked to serious infection risk in older people with RA

Older people with rheumatoid arthritis are not at increased risk for hospitalization with infection when receiving targeted therapy with biologics or JAK inhibitors rather than methotrexate, Japanese researchers report.

16-06-2022 | Rheumatology | News | Article

Anti-PTM antibodies warrant further investigation as markers for neuropsychiatric SLE

People with systemic lupus erythematosus are more likely to have autoantibodies against post-translationally modified proteins than healthy controls, and these antibodies are associated with neuropsychiatric manifestations, researchers report in RMD Open.

This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.

09-06-2022 | Rheumatology | News | Article

Reduced methotrexate dose noninferior to higher dose at adalimumab initiation in RA

Findings from the MIRACLE study indicate that patients with rheumatoid arthritis and inadequate response to methotrexate who receive a reduced dose of methotrexate at adalimumab initiation have comparable remission outcomes to those given the maximum tolerable dose, and may have fewer adverse events.

08-06-2022 | Rheumatology | News | Article

Maternal, fetal morbidity rates remain high in SLE

Research presented at the EULAR 2022 Congress in Copenhagen, Denmark, suggests that maternal and fetal morbidity remain high among pregnant women with systemic lupus erythematosus, despite reductions in mortality in recent decades.

08-06-2022 | Rheumatology | News | Article

NSAID suppression of axSpA spinal progression greatest with COX-2 selective inhibitors

Ten-year results from the GESPIC study support the use of NSAIDs for reducing radiographic spinal progression in patients with axial spondyloarthritis and suggest a stronger effect with cyclo-oxygenase-2 selective inhibitors than non-selective NSAIDs.

07-06-2022 | Rheumatology | News | Article

Call for CV risk assessment when starting tofacitinib in patients with PsA

Study findings support a move to assess cardiovascular risk and monitor for malignancies in patients with psoriatic arthritis and psoriasis taking the Janus kinase inhibitor tofacitinib.

06-06-2022 | Rheumatology | News | Article

DMARD treatment has ‘profound anticoagulant effects’ in early RA

Analysis of data from the NORD-STAR study suggests that people with early rheumatoid arthritis have increased levels of coagulation biomarkers, putting them at increased risk for venous thromboembolism, and initial treatment with DMARDs can help reduce this imbalance.

05-06-2022 | Rheumatology | News | Article

Deucravacitinib warrants further investigation for SLE

The phase 2 PAISLEY study suggests that the tyrosine kinase 2 inhibitor deucravacitinib may be a promising novel therapeutic option for systemic lupus erythematosus.

04-06-2022 | Rheumatology | News | Article

Sarilumab shows treatment promise in relapsing polymyalgia rheumatica

Phase 3 SAPHYR study findings suggest that the IL-6 receptor inhibitor sarilumab with glucocorticoid taper is an efficacious treatment option for patients with steroid-resistant polymyalgia rheumatica.

04-06-2022 | Rheumatology | News | Article

Bimekizumab beneficial for psoriatic arthritis in phase 3 trials

Bimekizumab has shown positive efficacy and safety results in the BE COMPLETE and BE OPTIMAL phase 3 psoriatic arthritis trials.

04-06-2022 | Rheumatology | News | Article

Support for pausing methotrexate only after second COVID-19 vaccine dose

Pausing methotrexate only after the second dose of a COVID-19 vaccine may provide the best balance between antibody response and risk for flare, findings from two randomized controlled trials suggest.

04-06-2022 | Rheumatology | News | Article

Mixed results for MACE risk with JAK inhibitors in RA

Two real-world studies looking at the risk for major cardiovascular events with JAK inhibitors versus TNF inhibitors in patients with rheumatoid arthritis show contradicting outcomes.

03-06-2022 | Rheumatology | News | Article

​​​​​​​The EULAR 2022 Debate: Will COVID-19 have a long-term impact on rheumatology practice?

At the EULAR 2022 Congress in Copenhagen, Denmark, two experts debated whether COVID-19 will have a lasting effect on rheumatology clinical practice.

03-06-2022 | Rheumatology | News | Article

Chronic, low-dose glucocorticoid benefits outweigh harms in senior patients with RA

Findings from the GLORIA trial suggest that older patients with established rheumatoid arthritis could benefit from 2 years of low-dose glucocorticoids in addition to their existing disease-modifying treatment with a favorable balance of benefit and harm.

03-06-2022 | Rheumatology | News | Article

OKINADA trial: No improvement in knee osteoarthritis symptoms with TNF inhibition

The tumor necrosis factor inhibitor adalimumab does not improve pain or function in people with knee osteoarthritis, indicate phase 2 trial results.